Why Pfizer (PFE) is on investors’ radar today

Pfizer (PFE) is back in focus as investors reassess the stock after a period of mixed returns, with the share price around $26.65 and a value score of 4 based on current metrics.

Recent trading has been choppy, with a 1-day share price return of a 0.78% decline and a 7-day share price return of a 3.37% decline. However, the 30-day and year to date share price returns of 3.90% and 5.84% suggest some cautious positive momentum, set against a 1-year total shareholder return of 8.69% and a weaker 3-year total shareholder return of a 23.50% decline.

If Pfizer’s mixed performance has you reassessing your watchlist, this could be a good moment to scout other healthcare names through our curated list of 27 healthcare AI stocks.

With Pfizer trading around $26.65, a value score of 4, an intrinsic discount estimate near 59% and a modest 7% gap to the average analyst target, you have to ask: is this a genuine mispricing, or is the market already accounting for potential future growth?

Most Popular Narrative: 13% Undervalued

At a last close of $26.65 versus a fair value of $30.62 in the most followed narrative, Pfizer is framed as offering a discount that hinges heavily on its future product pipeline and oncology expansion.

I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines. This should keep revenue flat, possibly growing in low to mid single digits in an optimistic scenario. Also, I think they will continue to release many new products that are already in phase 3 of research. If they're able to do this, maintain a 70% operational margin, increase profitability (by cutting costs, expanding margins etc.) and paying down debt, in the long term i see good anual returns (low double digits) from current stock price levels.

According to Francisco, Read the complete narrative.

This narrative focuses on how revenue and margins might align with the $30.62 fair value. It highlights oncology, late stage launches and potential profitability improvements, and raises the question of how these elements combine into a longer term return profile.

Result: Fair Value of $30.62 (UNDERVALUED)

However, this story can change quickly if oncology products underperform expectations, or if high debt and any potential dividend cut weigh more heavily on investor confidence.

Another View: Earnings Multiple Sends A Mixed Signal

While the most followed narrative points to a fair value of $30.62, the current P/E of 19.6x looks less clear cut when you compare it with the US Pharmaceuticals average of 19.6x and a peer average of 20.7x. Yet a fair ratio of 24.6x suggests the market could still shift its view. Is this a margin of safety or a signal that expectations may already be rich?

Next Steps

Mixed signals on valuation and sentiment can be confusing, so it helps to move fast and test the story against the numbers yourself, starting with 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If this Pfizer update has you thinking about what else might belong on your radar, now is the time to widen your search with a few focused screens.

• Target dependable income by reviewing our hand picked list of 15 dividend fortresses that may suit investors who prioritize regular cash returns.
• Hunt for potential value by checking our selection of 54 high quality undervalued stocks built from companies with quality fundamentals at prices that might look interesting.
• Guard your portfolio by scanning 87 resilient stocks with low risk scores so you can focus on businesses that currently carry lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.